Lung Cancer Clinical Trial

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

Summary

The primary hypotheses are that coformulated pembrolizumab/vibostolimab is superior to pembrolizumab alone with respect to (1) overall survival (OS) in participants with programmed cell death 1 ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%, TPS ≥1% and TPS 1% to 49%; and (2) progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by blinded independent central review (BICR), in participants with PD-L1 TPS ≥1% and TPS ≥50%.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Has a histologically or cytologically confirmed diagnosis of Stage IV: M1a, M1b, or M1c non-small cell lung cancer (NSCLC) per the American Joint Committee on Cancer (AJCC) Staging Manual, version 8
Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, as determined by the local site assessment
Has confirmation that epidermal growth factor receptor (EGFR)-, anaplastic lymphoma kinase (ALK)-, or reactive oxygen species proto-oncogene 1 (ROS1)-directed therapy is not indicated as primary therapy and absence of ALK and ROS1 gene rearrangements
Has provided tumor tissue that demonstrates Programmed Cell Death 1 Ligand 1 (PD-L1) expression in ≥1% of tumor cells as assessed by immunohistochemistry (IHC) at a central laboratory
Has an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 assessed within 7 days prior to randomization
Has a life expectancy of at least 3 months

A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

Is not a woman of childbearing potential (WOCBP)
Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 120 days after the last dose of study intervention
Has adequate organ function

Exclusion Criteria:

Has a known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for at least 3 years since initiation of that therapy

Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC.

Prior treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant or chemoradiation therapy for nonmetastatic NSCLC is allowed as long as therapy was completed at least 6 months before the diagnosis of metastatic NSCLC.
Participants must have recovered from all AEs due to previous therapies to Grade ≤1 or baseline. Participants with Grade ≤2 neuropathy may be eligible. Participants with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement may be eligible.
Has received prior therapy with an anti-programmed cell death receptor 1 (PD-1), anti-programmed cell death receptor ligand 1 (PD-L1), or anti-programmed cell death receptor ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137)
Has received previous treatment with another agent targeting the T cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibition motif (ITIM) domains (TIGIT) receptor pathway
Has received radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease

Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Administration of killed vaccines is allowed.

Any licensed COVID-19 vaccine (including for Emergency Use) in a particular country is allowed in the study as long as they are mRNA vaccines, adenoviral vaccines, or inactivated vaccines. These vaccines will be treated just as any other concomitant therapy.
Investigational vaccines (i.e., those not licensed or approved for Emergency Use) are not allowed.
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention
Has known active or untreated CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable for at least 4 weeks by repeat imaging, clinically stable, and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention
Has severe hypersensitivity (≥Grade 3) to pembrolizumab/vibostolimab or pembrolizumab and/or any of its excipients
Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
Has a known history of interstitial lung disease. Lymphangitic spread of the NSCLC is not exclusionary.
Has an active infection requiring systemic therapy
Has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is required unless mandated by local health authority
Has a known history of Hepatitis B or known active Hepatitis C virus infection
Has a history or current evidence of any condition, therapy, or laboratory abnormality that prevents the participant from receiving platinum-doublet chemotherapy for first line NSCLC, or that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

1246

Study ID:

NCT04738487

Recruitment Status:

Recruiting

Sponsor:

Merck Sharp & Dohme LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 153 Locations for this study

See Locations Near You

Boca Raton Regional Hospital ( Site 0004)
Boca Raton Florida, 33486, United States More Info
Study Coordinator
Contact
561-955-4862
Illinois Cancer Care ( Site 0026)
Peoria Illinois, 61615, United States More Info
Study Coordinator
Contact
309-243-3000
Mercy Research - David C. Pratt Cancer Center ( Site 0025)
Saint Louis Missouri, 63141, United States More Info
Study Coordinator
Contact
314-251-7057
Mercy Research - Cancer and Hematology Center ( Site 0032)
Springfield Missouri, 65804, United States More Info
Study Coordinator
Contact
417-820-8099
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0022)
Mineola New York, 11501, United States More Info
Study Coordinator
Contact
516-351-5757
Memorial Sloan Kettering Cancer Center ( Site 0013)
New York New York, 10065, United States More Info
Study Coordinator
Contact
646-449-2097
Fox Chase Cancer Center-Hematology/Oncology ( Site 0030)
Philadelphia Pennsylvania, 19111, United States More Info
Study Coordinator
Contact
215-728-2451
Hospital São Carlos-Oncocentro Ce ( Site 0208)
Fortaleza Ceara, 60135, Brazil More Info
Study Coordinator
Contact
+55 853034-8677
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0201)
Natal Rio Grande Do Norte, 59075, Brazil More Info
Study Coordinator
Contact
558440095595
ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0206)
Ijui Rio Grande Do Sul, 98700, Brazil More Info
Study Coordinator
Contact
+555531950504
Irmandade da Santa Casa de Misericórdia de Porto Alegre-Centro de Pesquisa Novos Tratamentos em Cân
Porto Alegre Rio Grande Do Sul, 90050, Brazil More Info
Study Coordinator
Contact
555132148143
CEPON-Pesquisa Clínica ( Site 0209)
Florianópolis Santa Catarina, 88034, Brazil More Info
Study Coordinator
Contact
554833311553
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 0200)
São Paulo Sao Paulo, 01246, Brazil More Info
Study Coordinator
Contact
+55 11 3893-3530
Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0207)
São Paulo Sao Paulo, 04014, Brazil More Info
Study Coordinator
Contact
551134744278
Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA ( Site 0204)
Rio de Janeiro , 20231, Brazil More Info
Study Coordinator
Contact
+55 21 3207-6569
BC Cancer Victoria-Clinical Trials Unit ( Site 0107)
Victoria British Columbia, V8R 6, Canada More Info
Study Coordinator
Contact
2505195572
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0104)
Hamilton Ontario, L8V 5, Canada More Info
Study Coordinator
Contact
9053879495
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 0102)
Kingston Ontario, K7L 2, Canada More Info
Study Coordinator
Contact
6135496666
Lakeridge Health ( Site 0106)
Oshawa Ontario, L1G 2, Canada More Info
Study Coordinator
Contact
9055768711
James Lind Centro de Investigación del Cáncer ( Site 0711)
Temuco Araucania, 48008, Chile More Info
Study Coordinator
Contact
+56452982404
CIDO SpA-Oncology ( Site 0707)
Temuco Araucania, 48101, Chile More Info
Study Coordinator
Contact
569 5 798 31 73
IC La Serena Research ( Site 0710)
La Serena Coquimbo, 17204, Chile More Info
Study Coordinator
Contact
+56512386127
Clínica Puerto Montt ( Site 0713)
Puerto Montt Los Lagos, 55002, Chile More Info
Study Coordinator
Contact
+56998634501
Oncocentro Valdivia ( Site 0715)
Valdivia Los Rios, 51121, Chile More Info
Study Coordinator
Contact
+56232634933
Clinica Universidad Catolica del Maule-Oncology ( Site 0703)
Talca Maule, 34655, Chile More Info
Study Coordinator
Contact
+56712635600
FALP ( Site 0702)
Providencia Region M. De Santiago, 75009, Chile More Info
Study Coordinator
Contact
+56227067543
Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0712)
Santiago Region M. De Santiago, 75006, Chile More Info
Study Coordinator
Contact
+56991612199
Orlandi Oncologia ( Site 0700)
Santiago Region M. De Santiago, 75007, Chile More Info
Study Coordinator
Contact
56992214787
Bradfordhill ( Site 0701)
Santiago Region M. De Santiago, 84203, Chile More Info
Study Coordinator
Contact
+56229490970
Centro de Investigación Oncológica del Norte ( Site 0708)
Antofagasta , 12400, Chile More Info
Study Coordinator
Contact
+56552654147
The First Affiliated Hospital of Anhui Medical University ( Site 2022)
Hefei Anhui, 23002, China More Info
Study Coordinator
Contact
13956012561
Anhui Provincil Hospital South District-Respiratory Medicine Dept ( Site 2017)
Hefei Anhui, 23003, China More Info
Study Coordinator
Contact
18963789187
Cancer Hospital Chinese Academy of Medical Science-Oncology ( Site 2030)
Beijing Beijing, 10002, China More Info
Study Coordinator
Contact
010-87788029
Beijing Cancer hospital-intrathoratic deparmtment II ( Site 2001)
Beijing Beijing, 10014, China More Info
Study Coordinator
Contact
13701224460
Beijing Cancer hospital-Thoracic Cancer Department A ( Site 2003)
Beijing Beijing, 10014, China More Info
Study Coordinator
Contact
13521469355
Beijing Peking Union Medical College Hospital-pneumology department ( Site 2009)
Beijing Beijing, 10073, China More Info
Study Coordinator
Contact
010 69151169
Beijing Chest Hospital,Capital Medical University ( Site 2020)
Beijing Beijing, 10114, China More Info
Study Coordinator
Contact
15124754382
Chongqing Cancer Hospital-Medical Oncology ( Site 2028)
Chongqing Chongqing, 40003, China More Info
Study Coordinator
Contact
02365075648
Army Medical Center of People's Liberation Army-respiratory ( Site 2025)
Chongqing Chongqing, 40004, China More Info
Study Coordinator
Contact
02368757791
Fujian Provincial Cancer Hospital-oncology department ( Site 2023)
Fuzhou Fujian, 35001, China More Info
Study Coordinator
Contact
0591-83660063
Fuzhou General hospital of Nanjing Military Command-Oncology Department ( Site 2029)
Fuzhou Fujian, 35002, China More Info
Study Coordinator
Contact
0591-22859663
Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine (
Guangzhou Guangdong, 51051, China More Info
Study Coordinator
Contact
13632102245
Harbin Medical University Cancer Hospital ( Site 2006)
Harbin Heilongjiang, 15000, China More Info
Study Coordinator
Contact
+86 13804552752
Henan Cancer Hospital ( Site 2015)
Zhengzhou Henan, 45000, China More Info
Study Coordinator
Contact
400-0371-818
Wuhan Union Hospital-Medical Oncology ( Site 2019)
Wuhan Hubei, 43002, China More Info
Study Coordinator
Contact
027-85726114
Xiangya Hospital Central South University-Respiratory -Asthma&COPD ( Site 2026)
Changsha Hunan, 41000, China More Info
Study Coordinator
Contact
13816876841
Hunan Cancer Hospital-thoracic oncology II ( Site 2013)
Changsha Hunan, 41001, China More Info
Study Coordinator
Contact
86 13170419973
Northern Jiangsu People's Hospital-General Surgery Department ( Site 2016)
Yangzhou Jiangsu, 22500, China More Info
Study Coordinator
Contact
13813194298
Jilin Cancer Hospital-oncology department ( Site 2000)
Changchun Jilin, 13200, China More Info
Study Coordinator
Contact
0431-80596022
Tang Du Hospital ( Site 2004)
Xi'an Shaanxi, 71003, China More Info
Study Coordinator
Contact
+86 18629190366
The First Affiliated Hospital of Xian Jiaotong University wa-Oncology ( Site 2012)
Xi'an Shaanxi, 71006, China More Info
Study Coordinator
Contact
02985323473
LinYi Cancer Hospital ( Site 2034)
Linyi Shandong, 27600, China More Info
Study Coordinator
Contact
15963998868
Linyi People's Hospital-Oncology ( Site 2035)
Linyi Shandong, , China More Info
Study Coordinator
Contact
18353975527
Fudan University Shanghai Cancer Center ( Site 2032)
Shanghai Shanghai, 20003, China More Info
Study Coordinator
Contact
+86 02164175590
West China Hospital Sichuan University-respiratory ( Site 2018)
Cheng Du Sichuan, 61004, China More Info
Study Coordinator
Contact
02885422114
Zhejiang Cancer Hospital-Breast Oncology ( Site 2008)
Hangzhou Zhejiang, 31002, China More Info
Study Coordinator
Contact
86 13858182310
The Second Affiliated hospital of Zhejiang University school of medicine-Respiratory Medicine ( Site
Hangzhou Zhejiang, 31005, China More Info
Study Coordinator
Contact
13816876841
The Second Affiliated hospital of Zhejiang University school of medicine-Respiratory Medicine ( Site
Hangzhou Zhejiang, 31005, China More Info
Study Coordinator
Contact
+86 13958194313
Taizhou Hospital of Zhejiang Province-Respiratory ( Site 2027)
Linhai Zhejiang, 31700, China More Info
Study Coordinator
Contact
13867622009
The First Affiliated Hospital of Wenzhou Medical University-Respiratory department ( Site 2031)
Wenzhou Zhejiang, 32500, China More Info
Study Coordinator
Contact
13587600968
Intervasc ( Site 0306)
Guatemala City , 01010, Guatemala More Info
Study Coordinator
Contact
+50259042511
CELAN,S.A ( Site 0304)
Guatemala , 01010, Guatemala More Info
Study Coordinator
Contact
+50242142081
Gastrosoluciones ( Site 0302)
Guatemala , 01010, Guatemala More Info
Study Coordinator
Contact
+50245711895
INTEGRA Cancer Institute ( Site 0303)
Guatemala , 01010, Guatemala More Info
Study Coordinator
Contact
+502 54530410
Oncomedica-Guatemala ( Site 0301)
Guatemala , 01010, Guatemala More Info
Study Coordinator
Contact
+50256973689
Grupo Medico Angeles-Grupo Medico Angeles ( Site 3007)
Guatemala , 01015, Guatemala More Info
Study Coordinator
Contact
+50257042323
Hong Kong Integrated Oncology Centre ( Site 1301)
Central , 00000, Hong Kong More Info
Study Coordinator
Contact
+85237006888
Queen Mary Hospital ( Site 1303)
Hksar , , Hong Kong More Info
Study Coordinator
Contact
+85222554361
Hong Kong United Oncology Centre ( Site 1302)
Jordan , , Hong Kong More Info
Study Coordinator
Contact
+85223868002
Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1201)
Kecskemét Bacs-Kiskun, 6000, Hungary More Info
Study Coordinator
Contact
+3676519853
Békés Megyei Központi Kórház Pándy Kálmán Tagkórház-Megyei Onkológiai Centrum ( Site 1207)
Gyula Bekes, 5700, Hungary More Info
Study Coordinator
Contact
+36665265262528
Petz Aladar Egyetemi Oktato Korhaz-Pulmonológia ( Site 1205)
Gyor Gyor-Moson-Sopron, 9024, Hungary More Info
Study Coordinator
Contact
+3696507900
Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 1200)
Szolnok Jasz-Nagykun-Szolnok, 5004, Hungary More Info
Study Coordinator
Contact
+3656503603
Országos Korányi Pulmonológiai Intézet-XIV. Tüdöbelgyógyászat ( Site 1204)
Budapest Pest, 1121, Hungary More Info
Study Coordinator
Contact
+3613913351
Torokbalint Tudogyogyintezet-Onkopulmonologiai Jarobeteg Centrum ( Site 1208)
Törökbálint Pest, 2045, Hungary More Info
Study Coordinator
Contact
+36307005601
Zala Megyei Szent Rafael Kórház-Pulmonológia ( Site 1202)
Zalaegerszeg Zala, 8900, Hungary More Info
Study Coordinator
Contact
+3692501527
Semmelweis University-Pulmonológiai Klinika ( Site 1209)
Budapest , 1083, Hungary More Info
Study Coordinator
Contact
+3614591500
National Hospital Organization Nagoya Medical Center ( Site 1920)
Nagoya Aichi, 460-0, Japan More Info
Study Coordinator
Contact
+81-52-951-1111
Fujita Health University ( Site 1906)
Toyoake Aichi, 470-1, Japan More Info
Study Coordinator
Contact
+81-562-93-2111
Ehime University Hospital ( Site 1911)
Toon Ehime, 790-0, Japan More Info
Study Coordinator
Contact
+81-89-964-5111
Kurume University Hospital ( Site 1912)
Kurume Fukuoka, 830-0, Japan More Info
Study Coordinator
Contact
+81-942-35-3311
Gunma Prefectural Cancer Center ( Site 1925)
Otashi Gunma, 373-8, Japan More Info
Study Coordinator
Contact
+81-276-38-0771
National Hospital Organization Hokkaido Cancer Center ( Site 1923)
Sapporo Hokkaido, 003-0, Japan More Info
Study Coordinator
Contact
+81-11-811-9111
Takarazuka City Hospital ( Site 1924)
Takarazuka Hyogo, 66508, Japan More Info
Study Coordinator
Contact
+81-797-87-1161
Kanagawa Cardiovascular and Respiratory Center ( Site 1921)
Yokohama Kanagawa, 236-0, Japan More Info
Study Coordinator
Contact
+81-45-701-9581
Kanagawa cancer center ( Site 1916)
Yokohama Kanagawa, 241-8, Japan More Info
Study Coordinator
Contact
+81-45-520-2222
Sendai Kousei Hospital ( Site 1900)
Sendai Miyagi, 98008, Japan More Info
Study Coordinator
Contact
+81-22-222-6181
Niigata Cancer Center Hospital ( Site 1904)
Niigata-shi Niigata, 951-8, Japan More Info
Study Coordinator
Contact
+81-25-266-5111
Kansai Medical University Hospital ( Site 1914)
Hirakata Osaka, 573-1, Japan More Info
Study Coordinator
Contact
+81-72-804-0101
Kindai University Hospital- Osakasayama Campus ( Site 1907)
Osaka-sayama Osaka, 589-8, Japan More Info
Study Coordinator
Contact
+81-72-366-0221
National Hospital Organization Kinki-chuo Chest Medical Center-Department of Thoracic Oncology ( Sit
Sakai Osaka, 591-8, Japan More Info
Study Coordinator
Contact
+81-72-252-3021
Osaka Medical and Pharmaceutical University Hospital ( Site 1908)
Takatsuki Osaka, 569-8, Japan More Info
Study Coordinator
Contact
+81-72-683-1221
Shizuoka Cancer Center ( Site 1905)
Nagaizumi Shizuoka, 411-8, Japan More Info
Study Coordinator
Contact
+81-55-989-5222
Tochigi Cancer Center ( Site 1927)
Utsunomiya Tochigi, 320-0, Japan More Info
Study Coordinator
Contact
+81-28-658-5151
Chiba University Hospital-Medical Oncology ( Site 1926)
Chiba , 260-8, Japan More Info
Study Coordinator
Contact
+81-43-222-7171
Okayama University Hospital ( Site 1913)
Okayama , 700-8, Japan More Info
Study Coordinator
Contact
+81-86-223-7151
Osaka International Cancer Institute ( Site 1915)
Osaka , 541-8, Japan More Info
Study Coordinator
Contact
+81669451181
Tokushima University Hospital ( Site 1917)
Tokushima , 770-8, Japan More Info
Study Coordinator
Contact
+81-88-631-3111
Juntendo University Hospital ( Site 1902)
Tokyo , 113-8, Japan More Info
Study Coordinator
Contact
+81-3-3813-3111
Japanese Foundation for Cancer Research ( Site 1901)
Tokyo , 135-8, Japan More Info
Study Coordinator
Contact
+81-3-3520-0111
Wakayama Medical University Hospital ( Site 1910)
Wakayama , 641-8, Japan More Info
Study Coordinator
Contact
+81-73-447-2300
Chungbuk National University Hospital-Internal medicine ( Site 1406)
Cheongju-si Chungbuk, 28644, Korea, Republic of More Info
Study Coordinator
Contact
+82-42-269-8760
Seoul National University Bundang Hospital ( Site 1403)
Seongnam Kyonggi-do, 13620, Korea, Republic of More Info
Study Coordinator
Contact
+82-31-1588-3369
The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 1405)
Suwon-si Kyonggi-do, 16247, Korea, Republic of More Info
Study Coordinator
Contact
+82-31-1577-8588
Seoul National University Hospital ( Site 1401)
Seoul , 03080, Korea, Republic of More Info
Study Coordinator
Contact
+82-2-2072-2995
Severance Hospital, Yonsei University Health System ( Site 1402)
Seoul , 03722, Korea, Republic of More Info
Study Coordinator
Contact
+82-2-1599-1004
Asan Medical Center ( Site 1400)
Seoul , 05505, Korea, Republic of More Info
Study Coordinator
Contact
+82-2-3010-3214
University Malaya Medical Centre ( Site 1504)
Lembah Pantai Kuala Lumpur, 59100, Malaysia More Info
Study Coordinator
Contact
+60378414000
Hospital Tengku Ampuan Afzan ( Site 1502)
Kuantan Pahang, 25100, Malaysia More Info
Study Coordinator
Contact
+6095572923
Gleneagles Penang Medical Center-Clinical Research Center (CRC) ( Site 1503)
George Town Pulau Pinang, 10050, Malaysia More Info
Study Coordinator
Contact
6042225685
Hospital Pulau Pinang ( Site 1501)
George Town Pulau Pinang, 10990, Malaysia More Info
Study Coordinator
Contact
6042225768
National Cancer Institute ( Site 1505)
Putrajaya Wilayah Persekutuan Putrajaya, 62250, Malaysia More Info
Study Coordinator
Contact
60388925555
Actualidad Basada en la Investigación del Cáncer-Lung Cancer ( Site 0411)
Guadalajara Jalisco, 44680, Mexico More Info
Study Coordinator
Contact
+523316395372
Centro de Investigacion Clinica Chapultepec ( Site 0400)
Morelia Michoacan, 58260, Mexico More Info
Study Coordinator
Contact
+524431478545
iCan Oncology Center Centro Medico AVE ( Site 0405)
Monterrey Nuevo Leon, 64710, Mexico More Info
Study Coordinator
Contact
+528125558169
Medical Care and Research SA de CV ( Site 0409)
Merida Yucatan, 97070, Mexico More Info
Study Coordinator
Contact
+529999203879
Centro Oncologico de Chihuahua-Unidad de Investigacion Clinica ( Site 0402)
Chihuahua , 31217, Mexico More Info
Study Coordinator
Contact
+526141803800
Human Science Research Trials ( Site 0406)
Mexico city , 14050, Mexico More Info
Study Coordinator
Contact
+525554073908
Oaxaca Site Management Organization ( Site 0403)
Oaxaca , 68000, Mexico More Info
Study Coordinator
Contact
+529515147056
UNIDAD DE ONCOLOGIA HOSPITAL NACIONAL ADOLFO GUEVARA VELASCO ESSSALUD CUSCO ( Site 0504)
Cusco Qusqu, CUSCO, Peru More Info
Study Coordinator
Contact
+51987531715
Clínica Internacional - Sede San Borja ( Site 0506)
Lima , 15036, Peru More Info
Study Coordinator
Contact
+51992004083
INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 0500)
Lima , 15038, Peru More Info
Study Coordinator
Contact
+51993473019
Hospital Militar Central Luis Arias Schereiber ( Site 0502)
Lima , 15076, Peru More Info
Study Coordinator
Contact
51997468543
Moscow Regional Oncological Dispensary ( Site 0812)
Balashikha Moskovskaya Oblast, 14390, Russian Federation
Hadassah Medical-Oncology department ( Site 0814)
Moscow Moskovskaya Oblast, 12120, Russian Federation
Central Clinical Hospital of the Presidential Administrative Department ( Site 0802)
Moscow Moskva, 12135, Russian Federation
Nizhegorodsky Regional Oncology Dispensary, Branch #2-chemotherapy ( Site 0809)
Nizhniy Novgorod Nizhegorodskaya Oblast, 60308, Russian Federation
GBUZ LOKB-Oncology department #1 ( Site 0804)
Saint-Petersburg Sankt-Peterburg, 19429, Russian Federation
Republican Clinical Oncology Dispensary ( Site 0805)
Kazan Tatarstan, Respublika, 42002, Russian Federation
Scientific research institution of oncology named after N.N. Petrov-Thoracic oncology ( Site 0803)
Sankt-Peterburg , 19775, Russian Federation
Wits Clinical Research ( Site 0900)
Johannesburg Gauteng, 2193, South Africa More Info
Study Coordinator
Contact
27113390600
LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 0901)
Pretoria Gauteng, 0181, South Africa More Info
Study Coordinator
Contact
+27826061150
Sandton Oncology Medical Group (Pty) Ltd-Research ( Site 0902)
Sandton Gauteng, 2196, South Africa More Info
Study Coordinator
Contact
27118830900
The Oncology Centre ( Site 0905)
Durban Kwazulu-Natal, 4091, South Africa More Info
Study Coordinator
Contact
+27312088666
Cape Town Oncology Trials ( Site 0903)
Cape Town Western Cape, 7570, South Africa More Info
Study Coordinator
Contact
+27219443832
Changhua Christian Hospital ( Site 1711)
Changhua County Changhua, 50006, Taiwan More Info
Study Coordinator
Contact
+886-4-7238595
Chang Gung Memorial Hospital at Kaohsiung ( Site 1702)
Kaohsiung Niao Sung Dist Kaohsiung, 83301, Taiwan More Info
Study Coordinator
Contact
+88677317123
National Taiwan University Hospital - Hsinchu branch ( Site 1704)
Hsinchu , 300, Taiwan More Info
Study Coordinator
Contact
+886353261514529
Taichung Veterans General Hospital-Chest ( Site 1707)
Taichung , 40705, Taiwan More Info
Study Coordinator
Contact
886-4-23592525 ext.3219
NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 1705)
Tainan , 704, Taiwan More Info
Study Coordinator
Contact
+886623535354559
National Taiwan University Hospital-Oncology ( Site 1706)
Taipei , 100, Taiwan More Info
Study Coordinator
Contact
+88622312345667511
Taipei Medical University Hospital ( Site 1712)
Taipei , 110, Taiwan More Info
Study Coordinator
Contact
+886-2-27372181
Mackay Memorial Hospital-Chest Medicine ( Site 1703)
Taipei , , Taiwan More Info
Study Coordinator
Contact
+886-25433535
Chulalongkorn University ( Site 1802)
Bangkok Krung Thep Maha Nakhon, 10330, Thailand More Info
Study Coordinator
Contact
+662-256-4533
Ramathibodi Clinical Research Centre ( Site 1801)
Bangkok Krung Thep Maha Nakhon, 10400, Thailand More Info
Study Coordinator
Contact
+6622011671
Faculty of Medicine Siriraj Hospital ( Site 1800)
Bangkok Krung Thep Maha Nakhon, 10700, Thailand More Info
Study Coordinator
Contact
+6624194489
Erciyes University Medical Oncology Department ( Site 1007)
Talas Kayseri, 38039, Turkey More Info
Study Coordinator
Contact
+903524374912
Hacettepe Universitesi-oncology hospital ( Site 1001)
Ankara , 06230, Turkey More Info
Study Coordinator
Contact
+903123052929
Memorial Ankara Hastanesi-Medical Oncology ( Site 1002)
Ankara , 06520, Turkey More Info
Study Coordinator
Contact
+903122536666
Gazi Universitesi-Oncology ( Site 1003)
Ankara , 06560, Turkey More Info
Study Coordinator
Contact
+903122025825
Acıbadem Maslak Hastanesi ( Site 1008)
İstanbul , 34457, Turkey More Info
Study Coordinator
Contact
905062979770
Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 1000)
Istanbul , 34668, Turkey More Info
Study Coordinator
Contact
+905324167355
Samsun Medical Park Hastanesi-medical oncology ( Site 1005)
Samsun , 55200, Turkey More Info
Study Coordinator
Contact
0903623114040
Cherkasy Regional Oncology Dispensary ( Site 1110)
Cherkassy Cherkaska Oblast, 18009, Ukraine
Chernihiv Medical Center of Modern Oncology-Clinical oncology and gynecology department ( Site 1113)
Chernihiv Chernihivska Oblast, 14029, Ukraine
Municipal Non-profit Enterprise City Clinical Hospital #4 of Dnipro City Council ( Site 1100)
Dnipro Dnipropetrovska Oblast, 49102, Ukraine
MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional-Chemotherapy department ( Site 1104)
Kryvyi Rih Dnipropetrovska Oblast, 50048, Ukraine
Communal Non-Commercial Enterprise Prykarpatski Clinical Oncological Center of Ivano-Frankivsk Regio
Ivano-Frankivsk Ivano-Frankivska Oblast, 1932, Ukraine
Institute of General and Emergency Surgery named after V.T. Zaitsev NAMS of Ukraine ( Site 1119)
Kharkiv Kharkivska Oblast, 61103, Ukraine
National Cancer Institute ( Site 1114)
Kyiv Kyivska Oblast, 03022, Ukraine
Vinnytsia Regional Clinical Oncological Hospital ( Site 1102)
Vinnytsia Vinnytska Oblast, 21029, Ukraine
Uzhgorod Central City Clinical Hospital-City oncology center ( Site 1120)
Uzhhorod Zakarpatska Oblast, 88000, Ukraine
Oncolife LLC-day-stay department ( Site 1107)
Zaporizhzhia Zaporizka Oblast, 69059, Ukraine
Zhytomyr Regional Oncology Center-Chemotherapy Department ( Site 1103)
Zhytomyr Zhytomyrska Oblast, 10002, Ukraine

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

1246

Study ID:

NCT04738487

Recruitment Status:

Recruiting

Sponsor:


Merck Sharp & Dohme LLC

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.